يعرض 1 - 10 نتائج من 27 نتيجة بحث عن '"Caroline Brard"', وقت الاستعلام: 0.96s تنقيح النتائج
  1. 1
    دورية أكاديمية
    P449: Fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva: Methodology of the randomized, double-blind, placebo-controlled phase II FALKON trial

    المؤلفون: Negar Karimian, Caroline Brard, Jeanna Cooper, Fei Shih

    المصدر: Genetics in Medicine Open, Vol 2, Iss , Pp 101343- (2024)

    مصطلحات موضوعية: Genetics, QH426-470, Medicine

    وصف الملف: electronic resource

    Relation: http://www.sciencedirect.com/science/article/pii/S2949774424004898; https://doaj.org/toc/2949-7744

    URL الوصول: https://doaj.org/article/61d4dddf7be34f78b878c159d0abdf4c

    Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study

    المؤلفون: Caroline Brard, Lisa V. Hampson, Nathalie Gaspar, Marie-Cécile Le Deley, Gwénaël Le Teuff

    المصدر: BMC Medical Research Methodology, Vol 19, Iss 1, Pp 1-17 (2019)

    مصطلحات موضوعية: Aggregate treatment effect, Bayesian randomised survival trial, Individual control data, Mixture prior, Power prior, Rare disease, Medicine (General), R5-920

    وصف الملف: electronic resource

    Relation: http://link.springer.com/article/10.1186/s12874-019-0714-z; https://doaj.org/toc/1471-2288

    URL الوصول: https://doaj.org/article/56c7c84340f8470582cb5e739d00ed1d

    Find this article in full text from Springer Verlag. Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  3. 3
    Table S2 from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

    المؤلفون: Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aa5d3e7b4d771f42fe8667c88c0ea8d
    https://doi.org/10.1158/1078-0432.22482161.v1

    أضف إلى المفضلة
  4. 4
    Data from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

    المؤلفون: Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130342ef5b960dbb0ebd0956b86de8bf
    https://doi.org/10.1158/1078-0432.c.6530840

    أضف إلى المفضلة
  5. 5
    Supplementary Figure Legends from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

    المؤلفون: Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d847eb45cb025e855425a9ce83ec5e1d
    https://doi.org/10.1158/1078-0432.22482167

    أضف إلى المفضلة
  6. 6
    Figure S3 from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

    المؤلفون: Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eccd81f44e2537fc5aa6d59e7ceb6dd
    https://doi.org/10.1158/1078-0432.22482170.v1

    أضف إلى المفضلة
  7. 7
    Abstract CT087: Phase I/II study of the WEE1 inhibitor adavosertib in combination with carboplatin in children with advanced malignancies: arm C of the AcSé-ESMART trial

    المؤلفون: Susanne A. Gatz, Anne C. Harttrampf, Caroline Brard, Francisco J. Bautista, Nicolas André, Samuel Abbou, Jonathan Rubino, Windy Rondof, Marc Deloger, Marc Rübsam, Daniel Hübschmann, Lynley V. Marshall, Souad Nebchi, Isabelle Aerts, Estelle Thebaud, Emilie De Carli, Anne-Sophie Defachelles, Xavier Paoletti, Robert Godin, Kowser Miah, Peter G. Mortimer, Gilles Vassal, Birgit Geoerger

    المصدر: Cancer Research. 83:CT087-CT087

    مصطلحات موضوعية: Cancer Research, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::df53d5d1a89a760884341d9caa75360a
    https://doi.org/10.1158/1538-7445.am2023-ct087

    أضف إلى المفضلة
  8. 8
    First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial

    المؤلفون: Raphael J. Morscher, Pablo Berlanga, Caroline Brard, Ludovic Lacroix, Birgit Geoerger, Nicolas André, Souad Nebchi, Gaëlle Pierron, Nadège Corradini, Gilles Vassal, G Schleiermacher, Lynley V. Marshall, Peter G. Mortimer, Emilie De Carli, Xavier Paoletti, Isabelle Aerts, Jonathan Rubino

    المساهمون: University of Zurich, Geoerger, Birgit, Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy], Institut Gustave Roussy (IGR), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Service de pédiatrie, d'hématologie et d'oncologie [Hôpital de La Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Institut Curie [Paris], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Léon Bérard [Lyon], AstraZeneca [Cambridge, UK], Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Unité de génétique et biologie des cancers (U830), Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Oak Foundation, AstraZeneca, Royal Marsden Cancer Charity, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, SNF, Fondation ARC pour la Recherche sur le Cancer, ARC, Institut National Du Cancer, INCa, Kurt und Senta Herrmann Stiftung, The ESMART and MAPPYACTS trials were supported by grants from the Institut National du Cancer (INCa), France through the AcSé program and the PHRC ‘INCa-DGOS_8519’ MERRI, the Association Imagine for Margo, France , Fondation ARC, France , the Fédération Enfants et Santé , the Société Française de lutte contre les Cancers et les leucémies de l’Enfant et l'adolescent (SFCE), France, Dell and AstraZeneca, France . B.G. is supported by the ‘Parrainage médecin-chercheur’ of Gustave Roussy. R.J.M. is supported by the Swiss National Science Foundation and the Kurt und Senta Herrmann Stiftung. L.V.M. is supported through the Oak Foundation via the Royal Marsden Cancer Charity., Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

    المصدر: European Journal of Cancer
    European Journal of Cancer, Elsevier, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩
    European Journal of Cancer, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩

    مصطلحات موضوعية: Oncology, Male, Dual mTOR inhibitor, Cancer Research, Administration, Oral, mTORC1, 0302 clinical medicine, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, Child, 0303 health sciences, education.field_of_study, Molecular enriched phase I/II, Vistusertib, 3. Good health, Treatment Outcome, Paediatric relapsed refractory cancer, 030220 oncology & carcinogenesis, Child, Preschool, Gain of Function Mutation, Benzamides, PI3K/AKT/mTOR pathway, 2730 Oncology, Female, medicine.drug, medicine.medical_specialty, Adolescent, Morpholines, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, 610 Medicine & health, Mechanistic Target of Rapamycin Complex 2, Mechanistic Target of Rapamycin Complex 1, 03 medical and health sciences, Young Adult, AZD2014, Internal medicine, Glioma, medicine, Temozolomide, Humans, education, Protein kinase B, 030304 developmental biology, Neoplasm Staging, business.industry, medicine.disease, Clinical trial, Pyrimidines, 10036 Medical Clinic, Topotecan, business

    وصف الملف: 1_s2.0_S095980492100527X_main.pdf - application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1a7dc4b095aacabf3e9c654b9c35db8
    https://pubmed.ncbi.nlm.nih.gov/34543871

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
  9. 9
    A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

    المؤلفون: Sara Faouzi, Caroline Brard, Jeremy Lupu, Isabelle Girault, Séverine Roy, Kristina Sorg, SuFey Ong, Emilie Routier, Shensi Shen, Caroline Robert, Sarah Warren, Pascale Morel, Julien Adam, Stéphan Vagner, Jean-Yves Scoazec

    المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research. 28(3)

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Programmed Cell Death 1 Receptor, Proximity ligation assay, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Transcriptome, Internal medicine, PD-L1, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Medicine, Humans, Immune Checkpoint Inhibitors, Melanoma, biology, business.industry, medicine.disease, Ipilimumab, Progression-Free Survival, Nivolumab, Treatment Outcome, Relative risk, Cohort, biology.protein, Biomarker (medicine), business, CD8

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcb295a0dde2f241f9c9500db9895e1c
    https://pubmed.ncbi.nlm.nih.gov/34785583

    أضف إلى المفضلة
  10. 10
    Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial

    المؤلفون: Francisco Bautista, Isabelle Aerts, Jonathan Rubino, Xavier Paoletti, Nicolas André, Stéphane Ducassou, Raphael J. Morscher, Anne-Sophie Defachelles, Souad Nebchi, Caroline Brard, Gilles Vassal, Emilie De Carli, Estelle Thebaud, Keyvan Rezai, Natasha K. A. van Eijkelenburg, Birgit Geoerger, Nadège Corradini

    المساهمون: University of Zurich, Geoerger, Birgit, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

    المصدر: Journal of Clinical Oncology
    Journal of Clinical Oncology, 2021, 39 (32), pp.3546-3560. ⟨10.1200/JCO.21.01152⟩

    مصطلحات موضوعية: Oncology, Male, Cancer Research, medicine.medical_specialty, Time Factors, Adolescent, Population, Aminopyridines, Ribociclib, [SDV.CAN]Life Sciences [q-bio]/Cancer, 610 Medicine & health, Internal medicine, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, medicine, Temozolomide, Humans, 1306 Cancer Research, Everolimus, education, Child, Protein Kinase Inhibitors, education.field_of_study, business.industry, Age Factors, Cancer, Cyclin-Dependent Kinase 4, Infant, Cyclin-Dependent Kinase 6, medicine.disease, Treatment Outcome, Purines, 10036 Medical Clinic, Child, Preschool, Topotecan, Female, 2730 Oncology, business, medicine.drug

    وصف الملف: PMID_34347542_jco.21.01152.pdf - application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ad6c0217a9283f838c29c6673782f74

    View record in Lippincott, Williams & Wilkins
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء